TWI755629B - 含鎮靜藥物之緩釋藥物組合物及其用途 - Google Patents

含鎮靜藥物之緩釋藥物組合物及其用途 Download PDF

Info

Publication number
TWI755629B
TWI755629B TW108132920A TW108132920A TWI755629B TW I755629 B TWI755629 B TW I755629B TW 108132920 A TW108132920 A TW 108132920A TW 108132920 A TW108132920 A TW 108132920A TW I755629 B TWI755629 B TW I755629B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
lipid
dexmedetomidine
liposome
sedative drug
Prior art date
Application number
TW108132920A
Other languages
English (en)
Chinese (zh)
Other versions
TW202023618A (zh
Inventor
洪基隆
高特尼 沃爾特
高顥文
林宜諭
Original Assignee
台灣微脂體股份有限公司
美商Tlc生物醫藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 台灣微脂體股份有限公司, 美商Tlc生物醫藥公司 filed Critical 台灣微脂體股份有限公司
Publication of TW202023618A publication Critical patent/TW202023618A/zh
Application granted granted Critical
Publication of TWI755629B publication Critical patent/TWI755629B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW108132920A 2018-09-13 2019-09-12 含鎮靜藥物之緩釋藥物組合物及其用途 TWI755629B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730713P 2018-09-13 2018-09-13
US62/730,713 2018-09-13

Publications (2)

Publication Number Publication Date
TW202023618A TW202023618A (zh) 2020-07-01
TWI755629B true TWI755629B (zh) 2022-02-21

Family

ID=69777824

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108132920A TWI755629B (zh) 2018-09-13 2019-09-12 含鎮靜藥物之緩釋藥物組合物及其用途

Country Status (6)

Country Link
US (1) US12629354B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849532A4 (cg-RX-API-DMAC7.html)
JP (1) JP7482487B2 (cg-RX-API-DMAC7.html)
CN (1) CN112654348A (cg-RX-API-DMAC7.html)
TW (1) TWI755629B (cg-RX-API-DMAC7.html)
WO (1) WO2020056102A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472158B2 (en) * 2019-02-27 2025-11-18 Vanderbilt University Methods of treating trigeminal nerve pain
WO2021211575A1 (en) * 2020-04-13 2021-10-21 The Regents Of The Univefisity Of California Compositions comprising propofol, ketamine, and non-opioid analgesic, and methods of use
CN116688137B (zh) * 2023-07-21 2024-05-14 中国医学科学院北京协和医院 一种基于核壳结构的药物组合物及应用
CN118986892A (zh) * 2024-09-29 2024-11-22 济南大学 一种醋酸阿比特龙胆盐脂质体组合物及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5942241A (en) 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
IL140892A0 (en) 1998-08-12 2002-02-10 Yissum Res Dev Co Liposomal bupivacaine compositions prepared using an ammonium sulfate gradient
AU2003298738A1 (en) 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
AU2005281352B2 (en) * 2004-09-09 2011-01-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
CN101756902B (zh) * 2008-12-23 2011-10-05 上海医药工业研究院 一种可乐定多囊脂质体及其制备方法
BR112013016365A2 (pt) 2010-12-27 2018-06-26 Terumo Corp composição de lipossoma e processo para produção do mesmo
US20130096170A1 (en) * 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
KR102310786B1 (ko) 2013-02-01 2021-10-12 존원 파마, 인코포레이티드 리포좀 내로 난수용성 약물의 원격 부하
EP2968145A1 (en) 2013-03-13 2016-01-20 Mallinckrodt LLC Modified docetaxel liposome formulations
CN109350600B (zh) 2013-03-15 2021-10-29 台湾微脂体股份有限公司 设计脂质体水相和非水相部分的组成来控制药物的释放趋势
WO2016141167A1 (en) * 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
US9931298B2 (en) 2015-05-26 2018-04-03 Comfort Care For Animals Llc Liposome loading
EP3359134B1 (en) * 2015-10-08 2025-04-09 The Children's Medical Center Corporation Compositions and compositions for use in on-demand high-efficiency triggerable anesthesia
EP3936153B1 (en) 2016-01-11 2024-08-21 Celator Pharmaceuticals, Inc. Inhibiting ataxia telangiectasia and rad3-related protein (atr)
EP3829539A4 (en) 2018-08-02 2022-05-04 Taiwan Liposome Company, Ltd. DELAYED RELEASE COMPOSITIONS WITH A THERAPEUTIC AGENT FOR THE TREATMENT OF DEPRESSION OR ANXIETY AND USES THEREOF
WO2020033195A1 (en) 2018-08-08 2020-02-13 Taiwan Liposome Co., Ltd. Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof

Also Published As

Publication number Publication date
WO2020056102A1 (en) 2020-03-19
CN112654348A (zh) 2021-04-13
EP3849532A4 (en) 2022-06-08
EP3849532A1 (en) 2021-07-21
JP7482487B2 (ja) 2024-05-14
JP2022500398A (ja) 2022-01-04
TW202023618A (zh) 2020-07-01
US12629354B2 (en) 2026-05-19
US20220054455A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
TWI776076B (zh) 含有治療失智症之治療劑的緩釋藥物組合物及其用途
US12629354B2 (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
KR20150034200A (ko) 복막 투석용 리포좀 조성물
TWI767133B (zh) 含有治療憂鬱症或焦慮症之治療劑的緩釋組合物及其用途
TWI786328B (zh) 緩釋眼用藥物組合物及其用途
TWI772664B (zh) 含有抗精神病藥物的緩釋藥物組合物及其用途
TWI767149B (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40046574A (en) Sustained-release pharmaceutical compositions comprising of a sedative drug and uses thereof
TWI850208B (zh) 緩釋型翠普登組成物及其經皮下或類似途徑使用之方法
HK40054350A (zh) 含有免疫調節劑的緩釋藥物組合物及其用途
HK40045697A (en) Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
HK40043627A (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating dementia and uses thereof
HK40046579A (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
HK40046579B (en) Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof
EP3880176A1 (en) Sustained-release pharmaceutical compositions comprising a therapeutic agent for treating diseases due to reduced bone density or cartilage loss and uses thereof